Evaluation of Multi-Cancer Early Detection Testing in a High-Risk Military Population: The Sentinel Study

The purpose of this research study is to evaluate the possible benefits of an
investigational, but commercially available Galleri multi-cancer early detection (MCED)
blood test which is designed to detect many types of cancer early in veterans who have
served in the military in active duty.

The name of the screening blood test being studied is:

-GRAIL Galleri MCED test

Inclusion Criteria:

- Active-duty military service for eight or more years

- Age ≥ 45

- Received care at a VA facility within past 5 years

- Able to sign informed consent

- Willingness to travel to Dana-Farber Cancer Institute in Boston, MA, for diagnostic
testing if screening test indicates possible malignancy

Exclusion Criteria:

- Individuals diagnosed with invasive malignancy within 3 years of enrollment (non-
melanoma skin cancer is acceptable)

- Individuals with evidence of symptomatic or active cancer requiring therapeutic
intervention at the time of participation (hormone therapy for breast/prostate
cancer is acceptable)

- Individuals in the process of being evaluated for a clinical suspicion of cancer

- Individuals with known hematologic precursor disease (e.g., clonal hematopoiesis of
indeterminate potential (CHIP), monoclonal gammopathy of undetermined significance
(MGUS), which may result in a cancer signal detected on the MCED test)